Zoetis Inc. is the subject of a class action lawsuit alleging it misled investors about weakening sales of key animal health products, including Librela, Simparica Trio, Apoquel, and Cytopoint. The lawsuit claims Zoetis and its executives failed to disclose declining demand and increased competition, which led to significant stock price drops after quarterly financial disclosures from August 2025 to May 2026. Investors who bought Zoetis securities between January 2025 and May 2026 have until July 27, 2026, to seek lead plaintiff status in the case. This legal action highlights risks in Zoetis' companion animal product segment and could impact investor confidence going forward.
A class action lawsuit has been filed against Zoetis Inc. alleging the company misled investors about the strength of its Companion Animal segment. The lawsuit claims Zoetis portrayed this segment as a strong growth driver while hiding safety concern...
A class action lawsuit has been filed against Zoetis Inc. for allegedly misleading investors about the performance of its main animal health products, including Librela, Simparica Trio, Apoquel, and Cytopoint. The complaint claims Zoetis failed to di...
Zoetis Inc. reported flat net income of $601 million for Q1 2026 but lowered its full-year profit guidance due to weaker demand and increased price sensitivity among pet owners. Following this announcement, Zoetis's stock price fell sharply by 21.5%....
